Transient receptor potential ankyrin 1 (TRPA1) (TRPA1)

Transient receptor potential ankyrin 1 (TRPA1) is a non-selective cation channel that serves as a primary chemosensor for a wide array of noxious environmental irritants and endogenous inflammatory mediators [1, 8]. It is predominantly expressed in a subset of nociceptive sensory neurons, where its activation triggers the influx of calcium and sodium, leading to pain, itch, and the release of neuropeptides like CGRP and substance P that drive neurogenic inflammation [2, 10]. Beyond its role in sensory neurons, TRPA1 is found in various non-neuronal tissues, including the lungs, skin, and gastrointestinal tract, where it contributes to physiological processes like airway resistance and gut motility [1, 12]. In disease states, TRPA1 is heavily implicated in chronic pain conditions, migraine, asthma, and chronic cough, making it a high-priority target for drug development [5, 12]. Pharmacological intervention typically focuses on TRPA1 antagonists to alleviate hypersensitivity and inflammation, though the channel's broad expression profile necessitates careful consideration of off-target effects [5, 9]. Clinical candidates like GRC-17536 have demonstrated proof-of-concept in treating neuropathic pain, highlighting the therapeutic potential of modulating this versatile sensory integrator [5, 12].

Other names

ANKTM1Transient receptor potential cation channel subfamily A member 1Wasabi receptorTRP-ankyrin 1

TRPA1 acts as a non-selective cation channel that, when activated by noxious stimuli or irritants, allows the influx of calcium and sodium ions, leading to neuronal depolarization and the release of pro-inflammatory neuropeptides like CGRP and substance P [1, 10]. Therapeutic strategies primarily involve TRPA1 antagonism to block this signaling pathway, thereby reducing pain, itch, and neurogenic inflammation [5, 12]. Conversely, some agonists are used for desensitization or to exploit specific anti-inflammatory pathways in certain tissues [4, 7].